Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov. |
Louis Cantilena, Jr., M.D, Ph.D.
Associated Studies:
Division | Study Number | Title | Investigator(s) | Release Date |
---|---|---|---|---|
DTMC | NIDA-CPU-0011 | Ph1 Marinol Interaction Study - Part 1 | Louis Cantilena, Jr., M.D, Ph.D. | |
DTMC | NIDA-CPU-0010 | Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine | Louis Cantilena, Jr., M.D, Ph.D. | |
DTMC | NIDA-CPU-0005 | Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. | Louis Cantilena, Jr., M.D, Ph.D. | |
DTMC | NIDA-CPU-0003 | Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 | Louis Cantilena, Jr., M.D, Ph.D. | |
DTMC | NIDA-CPU-0002 | Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers | Louis Cantilena, Jr., M.D, Ph.D. |